One of most common mistakes that marketers make during a recession is to focus on cost rather than outcomes.
PRESIDENT AND CEO | PUROHIT NAVIGATION
One of most common mistakes that marketers make during a recession is to focus on cost rather than outcomes. For example, a comprehensive e-learning program may seem expensive initially, but over time it may deliver a greater return on investment, such as behavior conversion, long term loyalty, and heightened product awareness. Selecting tactics that provide amortized value is more effective than short term, less expensive tactics. Initiating a pharmacoeconomic study, say, can lead to various benefits that can be applied in more than one promotion, such as incorporating pivotal data into sales aids, communicating to managed care groups, and demonstrating value to physicians and patients.
Ahnal Purohit
The FDA's move of "acting in the best interest of consumers" may actually open a Pandora's box. It could allow a rise in advertising from online pharmacies, counterfeit drugs, and alternative therapies—all of which are easily available online and are not as strictly regulated as the pharmaceutical industry.
It will be some time before the FDA issues greater clarification on how to best approach online marketing. In the meantime, marketers do have choices. The first is to redesign their banner ads to include information, such as the generic name and fair balance, in a larger pixel-size format (good luck!). The larger format will incur additional costs for companies, so a closer analysis of the return on investment will need to be made.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
2 Commerce Drive
Cranbury, NJ 08512